Evidence map›Paper›PMID 32930962›Full record

ReviewBiophysical reviews2020

Invasive and non-invasive therapies for Alzheimer's disease and other amyloidosis.

Gaurav Pandey, Vibin Ramakrishnan

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Biophysical reviews, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Gaurav PandeyDepartment of Biosciences and Bioengineering, Indian Institute of Technology Guwahati, Guwahati, 781039, India.
Vibin RamakrishnanDepartment of Biosciences and Bioengineering, Indian Institute of Technology Guwahati, Guwahati, 781039, India. vibin@iitg.ac.in.ORCID http://orcid.org/0000-0002-8048-3211

Funding

Board of Research in Nuclear Sciences 35/14/07/2017-BRNSDepartment of Biotechnology , Ministry of Science and Technology BT/565/NE/U-Excel/2016
6 · The paper itself

Abstract

Advancements in medical science have facilitated in extending human lives. The increased life expectancy, though, has come at a cost. The cases of an aging population suffering from degenerative diseases like Alzheimer's disease (AD) are presently at its all-time high. Amyloidosis disorders such as AD are triggered by an abnormal transition of soluble proteins into their highly ordered aggregated forms. The landscape of amyloidosis treatment remains unchanged, and there is no cure for such disorders. However, an increased understanding of the mechanism of amyloid self-assembly has given hope for a possible therapeutic solution. In this review, we will discuss the current state of molecular and non-molecular options for therapeutic intervention of amyloidosis. We highlight the efficacy of non-invasive physical therapies as possible alternatives to their molecular counterparts. Graphical abstract.

Indexed as

AggregationAmyloid-betaNon-invasive therapiesProtein foldingProtein misfolding diseasesTau

Identifiers

PMID32930962
PMCPMC7575678

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.